Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7999598 | 1.00 | KDM4E (0.63) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL5599294 | 1.00 | KDM4E (0.63) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL6815850 | 0.94 | KDM4E (0.61) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL7646224 | 0.91 | KDM4E (0.53) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL7934243 | 0.89 | KDM4E (0.52) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL14837082 | 0.88 | KDM4E (0.55) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL2298043 | 0.87 | KDM4E (0.63) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL112331 | 0.87 | SMN1; SMN2 (0.63) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL14088106 | 0.87 | SMN1; SMN2 (0.63) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL112332 | 0.87 | SMN1; SMN2 (0.63) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140030323-A1 | CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION | TIARA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140030323-A1 | CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION | TIARA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8524772-B2 | Controlled release of N-acetylcysteine (NAC) for reduction of systemic and/or vascular inflammation | TIARA PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524772-B2 | Controlled release of N-acetylcysteine (NAC) for reduction of systemic and/or vascular inflammation | TIARA PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110244045-A1 | CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION | TIARA PHARMACEUTICALS ,INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110244045-A1 | CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION | TIARA PHARMACEUTICALS ,INC. (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2009137827-A2 | CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION | TIARA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030323-A1 | CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION | IL6, IL1B, NACA | KDM4E 4849/4885MAPT 2103/4885THRB 3934/4885 |
| US-20110244045-A1 | CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION | IL6, IL1B, NACA | KDM4E 4849/4885MAPT 2103/4885THRB 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.